PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Pemafibrate (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms PROMINENT-Eye Ancillary Study
- 03 Apr 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.